Objective:To investigate the safety and efficacy of Pipeline embolization device (PED) Shield in intracranial unruptured saccular aneurysms.Methods:This is a retrospective cohort study; 124 patients with intracranial unruptured saccular aneurysms treated with PED Shield at Department of Cerebrovascular Surgery, Neurosurgery Center, Zhujiang Hospital, Southern Medical University from July 2023 to October 2024 were enrolled. Intraoperative device-related complications and occurrence of hemorrhagic and ischemic complications within 30 days of the procedure were recorded. The clinical results and imaging results (degrees of stent patency and aneurysm occlusion rate) 6 months after follow-up were statistically analyzed. Modified Rankin scale (mRS) score>2 was defined as poor prognosis in clinical follow-up, and grade D according to O'Kelly Marotta (OKM) classification was considered as complete aneurysm occlusion in imaging follow-up.Results:Eighty-seven females and 37 males, aged (56.44±12.17) years (ranging from 27 to 80 years) were enrolled, with a maximum aneurysm diameter of 5.12 (3.73, 7.24) mm. Among the 124 patients, incidence of intraoperative instrument-related complications was 6.5% (8/124); and within 30 days of the procedure, incidence of ischemic complications was 4.8% (6/124) and that of hemorrhagic complications was 1.6% (2/124). Eighty-four patients had a 6-month clinical follow-up, with 1 patient (1.2%) having poor prognosis. Eighty-four patients (67.7%) completed a 6-month imaging follow-up: complete occlusion rate of aneurysms was 82.1% (69/84), incidence of in-stent stenosis (stenosis degree ≥25%) was 4.8% (4/84), and no symptomatic in-stent stenosis was found.Conclusion:Result of this study shows that PED Shield may be an effective and safe clinical option for intracranial unruptured saccular aneurysms.

Objective:To investigate the safety and efficacy of Pipeline embolization device (PED) Shield in intracranial unruptured saccular aneurysms.Methods:This is a retrospective cohort study; 124 patients with intracranial unruptured saccular aneurysms treated with PED Shield at Department of Cerebrovascular Surgery, Neurosurgery Center, Zhujiang Hospital, Southern Medical University from July 2023 to October 2024 were enrolled. Intraoperative device-related complications and occurrence of hemorrhagic and ischemic complications within 30 days of the procedure were recorded. The clinical results and imaging results (degrees of stent patency and aneurysm occlusion rate) 6 months after follow-up were statistically analyzed. Modified Rankin scale (mRS) score>2 was defined as poor prognosis in clinical follow-up, and grade D according to O'Kelly Marotta (OKM) classification was considered as complete aneurysm occlusion in imaging follow-up.Results:Eighty-seven females and 37 males, aged (56.44±12.17) years (ranging from 27 to 80 years) were enrolled, with a maximum aneurysm diameter of 5.12 (3.73, 7.24) mm. Among the 124 patients, incidence of intraoperative instrument-related complications was 6.5% (8/124); and within 30 days of the procedure, incidence of ischemic complications was 4.8% (6/124) and that of hemorrhagic complications was 1.6% (2/124). Eighty-four patients had a 6-month clinical follow-up, with 1 patient (1.2%) having poor prognosis. Eighty-four patients (67.7%) completed a 6-month imaging follow-up: complete occlusion rate of aneurysms was 82.1% (69/84), incidence of in-stent stenosis (stenosis degree ≥25%) was 4.8% (4/84), and no symptomatic in-stent stenosis was found.Conclusion:Result of this study shows that PED Shield may be an effective and safe clinical option for intracranial unruptured saccular aneurysms.

Objective To investigate the expression level and diagnostic value of microRNA-373(miR-373)in gastric cancer.Methods A total of 80 patients with gastric cancer admitted to the Gastric Cancer Diagnosis and Treatment Center of Dongguan Third Clinical College of Guangdong Medical University from February 2021 to February 2023 were selected as the gastric cancer group.80 patients with benign gastric diseases who underwent gastroscopy in Dongguan Third Clinical College of Guangdong Medical University during the same period and did not have tumors by pathological examination were selected as the benign gastric disease group,and 80 healthy subjects who underwent the physical examination during the same period were selected as the control group.Serum samples were collected from the subjects,and the expression level of miR-373 was detec-ted by real-time quantitative polymerase chain reaction(qRT-PCR),and its correlation with clinicopathologi-cal features was analyzed.Serum carbohydrate antigen 199(CA199)and carcinoembryonic antigen(CEA)were detected by automatic chemiluminescence immunoassay.The diagnostic efficacy of miR-373,CA199 and CEA for gastric cancer was evaluated by receiver operating characteristic(ROC)curve.Results The expres-sion levels of serum miR-373,CA199 and CEA in gastric cancer group were higher than those in benign gastric disease group and control group,and the differences were statistically significant(P＜0.05).The expression level of miR-373 was closely related to tumor maximum diameter,lymph node metastasis and TNM stage in patients with gastric cancer(P＜0.05).ROC curve analysis showed that the area under the curve of miR-373,CA199 and CEA in the diagnosis of gastric cancer was(95i％CI:0.819-0.926),0.874(95％CI:0.813-0.921)and 0.836(95％CI:0.769-0.889),respectively.The diagnostic efficacy of miR-373 was better than that of traditional tumor markers CA199 and CEA.Conclusion miR-373 is highly expressed in gastric cancer tissues,and the expression level of miR-373 is related to the clinicopathological features of gastric cancer,which has high application value in the early diagnosis of gastric cancer.

0.05). After treatment the incidence of ED in therapy group was decreased to 46.3% vs control group of 63.7%(P